NOVATO, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Michael Smith, Chief Financial Officer will participate in the following investor conferences:
- SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day on Monday, February 23, 2015, at the JW Essex House in New York.
- Cowen and Company 35th Annual Healthcare Conference on Tuesday, March 3, 2015 at 8:40 a.m. ET/5:40 a.m. PT at The Boston Marriott Copley Place in Boston.
A live audio webcast from the Cowen and Company Healthcare Conference can be accessed in the "Investors & Media" section of the company website, www.raptorpharma.com, with an archived version available for up to 90 days following the conference.
About Raptor Pharmaceutical
Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.